Serum Proteomic Profiling for the Early Diagnosis of Colorectal Cancer

Fudan University547 enrolled

Overview

No ideal serum biomarker currently exists for the early diagnosis of colorectal cancer (CRC). Therefore, it is urgent that accurate and reliable serum biomarkers be identified.

Magnetic bead-based fractionation coupled with matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry (MALDI-TOF MS) was used to screen serum samples from CRC patients and healthy controls.

Study Type

OBSERVATIONAL

Enrollment

547

Conditions

Colorectal Neoplasms

Interventions

Serum proteomicsOTHER

magnetic bead-based fractionation coupled with matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry

Eligibility

Sex: ALLMin age: 18 YearsMax age: 90 YearsHealthy volunteers:

Medical Language ↔ Plain English

Patients with colorectal cancer Inclusion criteria * histologically confirmed colorectal cancer * aged 18 years or older * have provided written informed consent Exclusion criteria * refusal to participate Healthy controls Inclusion criteria * no cancer history * aged 18 years or older * have provided written informed consent Exclusion criteria * refusal to participate * have first-degree relative with a known history of colorectal cancer

Locations (1)

Zhongshan Hospital, Fudan University

Shanghai, Shanghai Municipality, China

Outcomes

Primary Outcomes

Serum peptide mass fingerprinting (PMF)

Compare PMF of the colorectal caner group and control group, and then build the model to distinguish patients with colorectal cancer and controls

Time frame: 2010.03-2012.05 (2 years)

Secondary Outcomes

Expressed peptide peaks

Find differentially expressed peptide peaks from the model and identify some ideal serum biomarkers for the early diagnosis of colorectal cancer

Time frame: 2010.03-2012.05 (2 years)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.